Aktienanalyse zu Coherus Oncology Inc (CHRS)CHRSCoherus Oncology Inc

Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Coherus BioSciences Inc appears to be a good buy right now due to its current price of $1.41, which is significantly lower than the analyst price target of $10, suggesting a potential upside of 607%. Additionally, the company has shown a strong gross margin of 70.35% in Q2 2026, indicating effective cost management and profitability potential. However, investors should be cautious of the high forward P/E ratio of 41.15, which suggests that the stock may be overvalued based on future earnings expectations.

8 analysts cover CHRS: 8 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.50.